Stocks and Investing Stocks and Investing
Fri, April 22, 2022

Do Kim Maintained (VRTX) at Hold with Increased Target to $249 on, Apr 22nd, 2022


Published on 2024-10-27 20:34:09 - WOPRAI, Do Kim
  Print publication without navigation


Do Kim of Piper Sandler, Maintained "Vertex Pharmaceuticals Incorporated" (VRTX) at Hold with Increased Target from $245 to $249 on, Apr 22nd, 2022.

Do has made no other calls on VRTX in the last 4 months.



There are 9 other peers that have a rating on VRTX. Out of the 9 peers that are also analyzing VRTX, 2 agree with Do's Rating of Hold. Following are those relevant analyst calls for the last 4 months


  • Brian Abrahams of "RBC Capital" Maintained at Hold and Held Target at $274 on, Wednesday, April 6th, 2022
  • Paul Matteis of "Stifel" Maintained at Hold with Increased Target to $222 on, Thursday, January 27th, 2022


These are the ratings of the 7 analyists that currently disagree with Do


  • Colin Bristow of "UBS" Maintained at Strong Buy with Increased Target to $325 on, Wednesday, April 13th, 2022
  • Mohit Bansal of "Wells Fargo" Maintained at Buy with Increased Target to $300 on, Tuesday, April 5th, 2022
  • Hartaj Singh of "Oppenheimer" Maintained at Buy with Increased Target to $350 on, Monday, April 4th, 2022
  • Liisa Bayko of "Evercore ISI Group" Maintained at Buy with Increased Target to $278 on, Friday, April 1st, 2022
  • Brian Skorney of "Baird" Maintained at Buy and Held Target at $240 on, Wednesday, March 23rd, 2022
  • Andrew Fein of "HC Wainwright & Co." Maintained at Strong Buy and Held Target at $275 on, Thursday, January 27th, 2022
  • Evan Seigerman of "BMO Capital" Upgraded from Hold to Buy and Increased Target to $274 on, Thursday, January 20th, 2022
Contributing Sources